In this issue:
Intensive immuno-chemotherapy for MCL
Rivaroxaban for extended thromboprophylaxis
GA101 promising in preclinical NHL testing
Assessing PET scans after chemotherapy
Chelation therapy in myelodysplastic syndrome
AMG 531 in low-risk myelodysplastic syndrome
Disease activity of NMT for follicular lymphoma
bortezomib/dexamethasone prior to ASCT
INCB018424 in Ph- myeloproliferative disorders
Plerixafor + G-CSF in non-Hodgkin’s lymphoma
Midostaurine in aggressive systemic mastocytosis
Azacitidine in higher-risk myelodysplastic syndrome
Download PDF